| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Endogenous Metabolite; Cyclooxygenase (COX); Lipoxygenase (LOX)[1]
|
|---|---|
| ln Vivo |
In a rat adjuvant-induced arthritis (AIA) model, dietary supplementation with arachidonic acid (1% w/w in feed for 7 weeks) significantly increased arachidonic acid content in paw tissues by 2.3-fold compared to control. However, it did not alter arthritis severity (measured by paw swelling and clinical scores) or paw prostaglandin E₂ (PGE₂) content, indicating no pro-inflammatory exacerbation.
Serum analysis confirmed elevated arachidonic acid levels in supplemented rats but showed no correlation with disease progression or systemic PGE₂ changes.[1] In animal modeling, arachidonic acid can be utilized to create an obese foot model. |
| Animal Protocol |
AIA Model: Female Lewis rats received 1% (w/w) arachidonic acid in standard chow for 7 weeks (starting 1 week pre-adjuvant injection). Arthritis was induced at day 0 by intradermal tail injection of heat-killed Mycobacterium tuberculosis in mineral oil. Paw swelling was measured weekly; tissues/serum were collected at endpoint for lipidomics and PGE₂ analysis.[1]
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Arachidonic acid has known human metabolites, including 17-HETE, 18-HETE, 8,9-EET, 20-HETE, 9-HETE, 8-HETE, 5-HETE, 11-HETE, 11,12-EET, 5,6-EET, 13-HETE, 7-HETE, 10-HETE, 12-HETE, 14,15-EET, 15-HETE, 16-HETE, and 19-HETE. |
| Toxicity/Toxicokinetics |
Toxicity Summary
Cosmetic Ingredient Review Conclusion: The safety of this ingredient for use in cosmetics has not been documented or confirmed. The CIR panel cannot conclude whether arachidonic acid is safe for use in cosmetics until relevant safety data are obtained and evaluated. Insufficient data and does not support the use of this ingredient in cosmetics. |
| References | |
| Additional Infomation |
Arachidonic acid is an ω-6 polyunsaturated fatty acid and a precursor of inflammatory eicosate such as PGE₂. This study shows that an increase in arachidonic acid content in tissues does not necessarily lead to an exacerbation of arthritis inflammation.
The separation between tissue arachidonic acid content and PGE₂ levels suggests that there are complex regulatory mechanisms in the biosynthesis of eicosate during chronic inflammation. [1] Arachidonic acid is a long-chain fatty acid belonging to the C20 polyunsaturated fatty acid family with four (Z) double bonds at positions 5, 8, 11, and 14. It is a human metabolite, an EC 3.1.1.1 (carboxylesterase) inhibitor, a Daphnia galeata metabolite, and a mouse metabolite. It is an eicosate-5,8,11,14-tetraenoic acid, an ω-6 fatty acid, and a long-chain fatty acid. It is the conjugate acid of arachidonic acid. It originates from the hydride of (5Z,8Z,11Z,14Z)-eicosano-5,8,11,14-tetraene. It has been reported that arachidonic acid is found in Agaricus blazei, Mortierella hygrophila, and other organisms with relevant data. Arachidonic acid is an unsaturated essential fatty acid. It is found in the adipose tissue of animals and humans, as well as in the liver, brain, and glandular organs, and is a component of animal phospholipids. It is synthesized from dietary linoleic acid and is a precursor to the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. (ChemID Plus) An unsaturated essential fatty acid. It is found in the adipose tissue of animals and humans, as well as in the liver, brain, and glandular organs, and is a component of animal phospholipids. It is synthesized from dietary linoleic acid and is a precursor to the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. |
| Molecular Formula |
C20H32O2
|
|---|---|
| Molecular Weight |
304.4669
|
| Exact Mass |
304.24
|
| Elemental Analysis |
C, 78.90; H, 10.59; O, 10.51
|
| CAS # |
506-32-1
|
| Related CAS # |
Arachidonic acid-d8;69254-37-1;Arachidonic acid-d5;123167-26-0;Arachidonic acid-d11;2692624-11-4
|
| PubChem CID |
444899
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
407.5±0.0 °C at 760 mmHg
|
| Melting Point |
−49 °C(lit.)
|
| Flash Point |
336.3±18.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.501
|
| LogP |
6.91
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
22
|
| Complexity |
362
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C(C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])/C(/[H])=C(/[H])\C([H])([H])/C(/[H])=C(/[H])\C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
YZXBAPSDXZZRGB-DOFZRALJSA-N
|
| InChi Code |
InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-
|
| Chemical Name |
(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid
|
| Synonyms |
arachidonic acid; 506-32-1; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; (all-Z)-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; all-cis-5,8,11,14-eicosatetraenoic acid; Arachidonsaeure;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~328.44 mM)
Ethanol : ~100 mg/mL (~328.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (32.84 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2844 mL | 16.4220 mL | 32.8440 mL | |
| 5 mM | 0.6569 mL | 3.2844 mL | 6.5688 mL | |
| 10 mM | 0.3284 mL | 1.6422 mL | 3.2844 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
